These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21419626)

  • 1. Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.
    Tran TD; Pryde DC; Jones P; Adam FM; Benson N; Bish G; Calo F; Ciaramella G; Dixon R; Duckworth J; Fox DN; Hay DA; Hitchin J; Horscroft N; Howard M; Gardner I; Jones HM; Laxton C; Parkinson T; Parsons G; Proctor K; Smith MC; Smith N; Thomas A
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2389-93. PubMed ID: 21419626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a highly potent series of TLR7 agonists.
    Jones P; Pryde DC; Tran TD; Adam FM; Bish G; Calo F; Ciaramella G; Dixon R; Duckworth J; Fox DN; Hay DA; Hitchin J; Horscroft N; Howard M; Laxton C; Parkinson T; Parsons G; Proctor K; Smith MC; Smith N; Thomas A
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5939-43. PubMed ID: 21885277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
    Roethle PA; McFadden RM; Yang H; Hrvatin P; Hui H; Graupe M; Gallagher B; Chao J; Hesselgesser J; Duatschek P; Zheng J; Lu B; Tumas DB; Perry J; Halcomb RL
    J Med Chem; 2013 Sep; 56(18):7324-33. PubMed ID: 23961878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine.
    Smith DB; Kalayanov G; Sund C; Winqvist A; Pinho P; Maltseva T; Morisson V; Leveque V; Rajyaguru S; Le Pogam S; Najera I; Benkestock K; Zhou XX; Maag H; Cammack N; Martin JA; Swallow S; Johansson NG; Klumpp K; Smith M
    J Med Chem; 2009 Jan; 52(1):219-23. PubMed ID: 19055482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
    Chen KX; Vibulbhan B; Yang W; Nair LG; Tong X; Cheng KC; Njoroge FG
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1105-9. PubMed ID: 19168351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).
    Fidock MD; Souberbielle BE; Laxton C; Rawal J; Delpuech-Adams O; Corey TP; Colman P; Kumar V; Cheng JB; Wright K; Srinivasan S; Rana K; Craig C; Horscroft N; Perros M; Westby M; Webster R; van der Ryst E
    Clin Pharmacol Ther; 2011 Jun; 89(6):821-9. PubMed ID: 21451504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
    Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
    J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication.
    Clark JL; Hollecker L; Mason JC; Stuyver LJ; Tharnish PM; Lostia S; McBrayer TR; Schinazi RF; Watanabe KA; Otto MJ; Furman PA; Stec WJ; Patterson SE; Pankiewicz KW
    J Med Chem; 2005 Aug; 48(17):5504-8. PubMed ID: 16107149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of subgenomic hepatitis C virus replication by 5'-O-masked analogues of 6-chloropurine-2'-deoxyriboside.
    Ikejiri M; Ohshima T; Kato K; Toyama M; Murata T; Shimotohno K; Maruyama T
    Nucleic Acids Symp Ser (Oxf); 2007; (51):439-40. PubMed ID: 18029775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.
    Venkatraman S; Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu YT; Lovey R; Hendrata S; Huang Y; Pan W; Parekh T; Pinto P; Popov V; Pike R; Ruan S; Santhanam B; Vibulbhan B; Wu W; Yang W; Kong J; Liang X; Wong J; Liu R; Butkiewicz N; Chase R; Hart A; Agrawal S; Ingravallo P; Pichardo J; Kong R; Baroudy B; Malcolm B; Guo Z; Prongay A; Madison V; Broske L; Cui X; Cheng KC; Hsieh Y; Brisson JM; Prelusky D; Korfmacher W; White R; Bogdanowich-Knipp S; Pavlovsky A; Bradley P; Saksena AK; Ganguly A; Piwinski J; Girijavallabhan V; Njoroge FG
    J Med Chem; 2006 Oct; 49(20):6074-86. PubMed ID: 17004721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.
    Horsmans Y; Berg T; Desager JP; Mueller T; Schott E; Fletcher SP; Steffy KR; Bauman LA; Kerr BM; Averett DR
    Hepatology; 2005 Sep; 42(3):724-31. PubMed ID: 16116638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
    Eldrup AB; Prhavc M; Brooks J; Bhat B; Prakash TP; Song Q; Bera S; Bhat N; Dande P; Cook PD; Bennett CF; Carroll SS; Ball RG; Bosserman M; Burlein C; Colwell LF; Fay JF; Flores OA; Getty K; LaFemina RL; Leone J; MacCoss M; McMasters DR; Tomassini JE; Von Langen D; Wolanski B; Olsen DB
    J Med Chem; 2004 Oct; 47(21):5284-97. PubMed ID: 15456273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor.
    Mittapalli GK; Zhao F; Jackson A; Gao H; Lee H; Chow S; Kaur MP; Nguyen N; Zamboni R; McKelvy J; Wong-Staal F; Macdonald JE
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4955-61. PubMed ID: 22784640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
    Hammerbeck DM; Burleson GR; Schuller CJ; Vasilakos JP; Tomai M; Egging E; Cochran FR; Woulfe S; Miller RL
    Antiviral Res; 2007 Jan; 73(1):1-11. PubMed ID: 16959331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists.
    Xie YF; Lake K; Ligsay K; Komandla M; Sircar I; Nagarajan G; Li J; Xu K; Parise J; Schneider L; Huang D; Liu J; Dines K; Sakurai N; Barbosa M; Jack R
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3367-72. PubMed ID: 17446072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate.
    Slater MJ; Amphlett EM; Andrews DM; Bravi G; Burton G; Cheasty AG; Corfield JA; Ellis MR; Fenwick RH; Fernandes S; Guidetti R; Haigh D; Hartley CD; Howes PD; Jackson DL; Jarvest RL; Lovegrove VL; Medhurst KJ; Parry NR; Price H; Shah P; Singh OM; Stocker R; Thommes P; Wilkinson C; Wonacott A
    J Med Chem; 2007 Mar; 50(5):897-900. PubMed ID: 17269759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and anti-HCV activity Of 2''-beta-hydroxymethylated nucleosides.
    Jeong LS; Yoo BN; Kim HO; Lee KM; Moon HR
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(6-7):725-8. PubMed ID: 18066889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors.
    Kang IJ; Wang LW; Yeh TK; Lee CC; Lee YC; Hsu SJ; Wu YS; Wang JC; Chao YS; Yueh A; Chern JH
    Bioorg Med Chem; 2010 Sep; 18(17):6414-21. PubMed ID: 20675142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
    Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activity of 5',9-anhydro-3-purine-isonucleosides as potential anti-hepatitis C virus agents.
    Chun BK; Wang P; Hassan A; Du J; Tharnish PM; Murakami E; Stuyver L; Otto MJ; Schinazi RF; Watanabe KA
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(1):83-97. PubMed ID: 17162589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.